Bibliography
- Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 2011;18:R1-4
- Giamas G, Filipovic A, Jacob J, Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011;15:715-19
- Stebbing J, Filipovic A, Ellis IO, LMTK3 expression in breast cancer: association with tumour phenotype and clinical outcome. Breast Cancer Res Treat 2011; published online 30 May 2011; doi: 10.1007/s10549-011-1622-z
- Johnson AB, O'Malley BW. Erasing breast cancer resistance through the kinome. Nat Med 2011;17:660-1
- Xu J, Wu R-C, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 2009;9:615-30
- Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010;19:1355-66
- Leighl NB, Dent S, Clemons M, A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2008;108:87-92
- Naik S, Dothager RS, Marasa J, Vascular endothelial growth factor is synthetic lethal to aberrant beta-catenin activation in colon cancer. Clin Cancer Res 2009;15:7529-37
- Tyner JW, Deininger MW, Loriaux M, RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA 2009;106:8695-700